Blinatumomab retreatment after relapse in patients with relapsed/refractory B-precursor acute lymphoblastic leukemia

M. S. Topp; M. Stelljes; G. Zugmaier; P. Barnette; L. T. Heffner; T. Trippett; J. Duell; R. C. Bargou; C. Holland; J. E. Benjamin; M. Klinger; M. R. Litzow

doi:10.1038/leu.2017.306

Blinatumomab retreatment after relapse in patients with relapsed/refractory B-precursor acute lymphoblastic leukemia

M. S. Topp, M. Stelljes, G. Zugmaier, P. Barnette, L. T. Heffner, T. Trippett, J. Duell, R. C. Bargou, C. Holland, J. E. Benjamin, M. Klinger, M. R. Litzow

Hematology

Research output: Contribution to journal › Letter › peer-review

15 Scopus citations

Original language	English (US)
Pages (from-to)	562-565
Number of pages	4
Journal	Leukemia
Volume	32
Issue number	2
DOIs	https://doi.org/10.1038/leu.2017.306
State	Published - Feb 1 2018

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.1038/leu.2017.306

Cite this

@article{51314dbbcc8a4fc38f318a472dd27906,

title = "Blinatumomab retreatment after relapse in patients with relapsed/refractory B-precursor acute lymphoblastic leukemia",

author = "Topp, {M. S.} and M. Stelljes and G. Zugmaier and P. Barnette and Heffner, {L. T.} and T. Trippett and J. Duell and Bargou, {R. C.} and C. Holland and Benjamin, {J. E.} and M. Klinger and Litzow, {M. R.}",

note = "Funding Information: We thank A Renneville, C Preudhomme (Lille), O Wagner-Ballon (Cr{\'e}teil) and E Solary (Villejuif) for helpful discussion, S Baulande from ICGex NGS platform of the Institut Curie and investigators of the Groupe Francophone des My{\'e}lodysplasies. This study received a research grant from Celgene and was conducted by two teams labeled by the SIRIC Cancer Research for PErsonalized Medicine CARPEM. OK received a CARPEM fellowship grant. Funding Information: MST: Research support and/or consulting fees from Amgen, Roche, Regeneron, Affimed, Jazz, Gilead and Pfizer. MS: Research grants from Pfizer. Consulting fees from Amgen, Pfizer and Jazz. Speakers bureau for Amgen and Pfizer. GZ, JEB: Employees and stockholders of Amgen. LTH: Research support from Amgen. Honoraria from Amgen and Pfizer. RCB: Consulting fees from Amgen, Novartis, AstraZeneca, Pfizer, Genmab, GEMoaB GmbH and Cellex. Patents/royalties for blinatumomab. CH: Employee and stockholder of Amgen. Stockholder of MacroGenics. MK: Employee and stockholder of Amgen. Inventor remuneration due to blinatumomab-related patent. MRL: Research grants from Amgen. The remaining authors declare no conflict of interest.",

year = "2018",

month = feb,

day = "1",

doi = "10.1038/leu.2017.306",

language = "English (US)",

volume = "32",

pages = "562--565",

journal = "Leukemia",

issn = "0887-6924",

publisher = "Nature Publishing Group",

number = "2",

}

TY - JOUR

T1 - Blinatumomab retreatment after relapse in patients with relapsed/refractory B-precursor acute lymphoblastic leukemia

AU - Topp, M. S.

AU - Stelljes, M.

AU - Zugmaier, G.

AU - Barnette, P.

AU - Heffner, L. T.

AU - Trippett, T.

AU - Duell, J.

AU - Bargou, R. C.

AU - Holland, C.

AU - Benjamin, J. E.

AU - Klinger, M.

AU - Litzow, M. R.

N1 - Funding Information: We thank A Renneville, C Preudhomme (Lille), O Wagner-Ballon (Créteil) and E Solary (Villejuif) for helpful discussion, S Baulande from ICGex NGS platform of the Institut Curie and investigators of the Groupe Francophone des Myélodysplasies. This study received a research grant from Celgene and was conducted by two teams labeled by the SIRIC Cancer Research for PErsonalized Medicine CARPEM. OK received a CARPEM fellowship grant. Funding Information: MST: Research support and/or consulting fees from Amgen, Roche, Regeneron, Affimed, Jazz, Gilead and Pfizer. MS: Research grants from Pfizer. Consulting fees from Amgen, Pfizer and Jazz. Speakers bureau for Amgen and Pfizer. GZ, JEB: Employees and stockholders of Amgen. LTH: Research support from Amgen. Honoraria from Amgen and Pfizer. RCB: Consulting fees from Amgen, Novartis, AstraZeneca, Pfizer, Genmab, GEMoaB GmbH and Cellex. Patents/royalties for blinatumomab. CH: Employee and stockholder of Amgen. Stockholder of MacroGenics. MK: Employee and stockholder of Amgen. Inventor remuneration due to blinatumomab-related patent. MRL: Research grants from Amgen. The remaining authors declare no conflict of interest.

PY - 2018/2/1

Y1 - 2018/2/1

UR - http://www.scopus.com/inward/record.url?scp=85042287965&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042287965&partnerID=8YFLogxK

U2 - 10.1038/leu.2017.306

DO - 10.1038/leu.2017.306

M3 - Letter

C2 - 28990581

AN - SCOPUS:85042287965

SN - 0887-6924

VL - 32

SP - 562

EP - 565

JO - Leukemia

JF - Leukemia

IS - 2

ER -

Blinatumomab retreatment after relapse in patients with relapsed/refractory B-precursor acute lymphoblastic leukemia

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this